Ixempra Gives Bristol New Start In Chemotherapy, Offers Refinement Of Taxol
Executive Summary
With FDA's approval of Ixempra (ixabepilone), Bristol-Myers Squibb is poised to launch a novel chemotherapy option that offers a refinement of its successful Taxol and activity in taxane resistant patients
You may also be interested in...
BMS Acquisition Strategy Heats Up With Kosan Buy
Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences
BMS Acquisition Strategy Heats Up With Kosan Buy
Bristol-Myers Squibb will jump full throttle into the race to bring to market a new class of oncology medicines, heat shock protein 90 inhibitors, after acquiring Kosan Biosciences
ODAC Split On Avastin Use In First-Line Metastatic Breast Cancer
FDA's Oncologic Drugs Advisory Committee creates a second obstacle to the approval of Genentech's Avastin in metastatic breast cancer by deciding that existing data do not establish a positive risk-benefit profile for a first-line indication. Genentech's primary obstacle is relying on a surrogate endpoint for full approval, in trying to use progression-free survival as a direct measure of clinical benefit